Publications by authors named "C F LeMaistre"
We analyzed access barriers to anti-CD19+ chimeric antigen receptor T-cells (CART) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. 357 intended recipients of FDA-approved anti-CD19+ CART were identified in the study period (2018 to 2022). Results showed that the median age at referral was 61 years, referral year was 2018 (4%), 2019 (14%), 2020 (18%), 2021 (26%), and 2022 (38%).
View Article and Find Full Text PDFThe treatment setting influences acute myeloid leukemia (AML) outcomes. Most cancer patients receive care in the community, yet few studies have evaluated the effectiveness of clinical programs outside of academic or National Cancer Institute (NCI)-designated cancer centers. This was a multi-level, case-controlled study of real-world outcomes for initial AML treatment in a community-based network for 1,391 patients with AML between 2011 and 2018.
View Article and Find Full Text PDFImmune effector cell (IEC) therapy represents a transformative advancement in oncology, leveraging the immune system to combat various malignancies. This article outlines a comprehensive framework for establishing and maintaining quality standards in IEC therapy amidst rapid scientific and clinical advancements. We emphasize the integration of structured process measures, robust quality assurance, and meticulous outcome evaluation to ensure treatment efficacy and safety.
View Article and Find Full Text PDFImpact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.
Transplant Cell Ther
October 2024
Article Synopsis
- - The study investigates the survival outcomes of patients receiving umbilical cord blood transplants (UCBT) across different racial and ethnic groups, focusing on Black, Latinx, White, and Asian patients, as previous research indicated disparities in survival rates.
- - A retrospective analysis of data from the Center for International Blood and Marrow Transplant Research (CIBMTR) included 983 single and 1529 double UCBT recipients, measuring outcomes like overall survival (OS), disease-free survival, and transplant-related mortality over two years.
- - Results showed that while overall survival rates varied by race/ethnicity, with Latinx patients having significantly lower OS compared to Blacks, no significant differences were observed in child patients,
Article Synopsis
- There has been an increase in the number of hematopoietic cell transplants (HCT) and improvement in overall survival after these procedures for blood disorders, but the impact on racial/ethnic minorities is unclear.
- A study examined transplant rates and survival trends among non-Hispanic Whites, non-Hispanic African Americans, and Hispanics from 2009 to 2018, revealing that Hispanics and non-Hispanic African Americans experienced higher rates of transplant than non-Hispanic Whites.
- Despite overall improvements in survival rates across groups, non-Hispanic African Americans faced greater mortality risks after allogeneic transplants, indicating ongoing disparities that need to be addressed.